Civica
Financial intelligence for Asia's healthcare markets
 
 
Remember me:

Analysis: What will drive medical inflation in 2017?

The Aon Asia Market Review 2017 report forecasts a net medical inflation rate of 6% in Asia for 2017, marginally down on the 6.3% recorded last year.

Within the region several countries have the unenviable distinction of posting double digit forecast increases for 2017. These include Indonesia, Malaysia, Pakistan, South Korea and Vietnam. Conversely, the key markets of China (3%) and Singapore (8.7%) are forecast to experience significant declines in medical inflation year-on-year.

The now well-established drivers of medical inflation globally include an ageing population, the proliferation of chronic or non-communicable diseases and advanced medical technology. All of these cost-drivers are evident in Asia.

Across the region, two of the chronic diseases most responsible for lost productivity and premature death are hypertension and type two diabetes. The World Health Organisation reports that high blood pressure is the leading risk factor for death, claiming 1.5 million lives each year in southeast Asia. One in three adults in the region is hypertensive.

The Asian Diabetes Prevention Initiative reports that 60% of the global diabetic population lives in Asia, with 113.9 million adults in China affected, representing 11.6% of the adult population. In 1980, the corresponding figure was less than 1%. In India, 65.1 million adults have diabetes. These numbers give China and India the dubious distinction of having the largest number of diabetes sufferers in the world. The high prevalence of these chronic illnesses is largely attributable to modifiable lifestyle behaviours.

Evidence suggests that middle-class consumers in emerging markets increase their spending on healthcare. This is attributable to several convergent factors: adaptation of western lifestyle, demand for improved health outcomes, inadequate public healthcare systems, and proliferation of private healthcare providers inclusive of advanced medical technology.

To illustrate the above point, international consultancy firm McKinsey has forecast that consumer healthcare spending in China will grow at a compound annual growth rate of 11.6% between 2005 and 2025 with India in close proximity of 9% over the same period.

Given the proliferation of chronic illness and the contributory impact of modifiable lifestyle behaviours related to diet, exercise, alcohol, tobacco, and stress, it is encouraging to note that medical plan insurers in several markets are increasing their commitment to wellness-related services. Looking to the future, these services will need to be more targeted, both with regard to addressing the co-morbidities that are driving the claims experience and engaging those demographics most at risk.

You can download the Aon Asia Market Review here.

Posted on: 08/02/2017 UTC+08:00


News

Union Medical Healthcare, the largest aesthetic medical service provider in Hong Kong, has said that it intends to change the use of the proceeds of its IPO.
Hong Kong-listed Hua Han Health Industry Holdings says that it is on course for the examination into the negative reports from Emerson Analytics last year to be completed by Grant Thornton by the end of the third quarter.
Hang Seng-listed China Medical & HealthCare Group expects to record a significant decrease in the loss attributable to the shareholders of the company for the year ended 30 June.
Beijing-based Symbow Medical, which develops surgical navigation devices, has raised Rmb120 million (US$17.8 million) Series A funding led by Huayi Capital. National Emerging Industry Guidance Fund, Shandong Buchang Pharmaceuticals, and Sangel Capital all participated.
International Healthway Corporation (IHC), a Singapore-listed integrated healthcare services and facilities provider, has warned that it expects to post a loss for the first and second quarters of the year. “The loss is mainly attributable to operating loss for 1Q2017 and impairment of certain receivables for 2Q2017, respectively,” the company said in a statement.
Medical glove manufacturer Careplus Group plans to raise M$18.9 million (US$4.4 million) via a private placement of shares. The group plans to sell 48.3 million shares at an indicative price of R$0.39 per share. RHB Investment Bank is managing the deal.
Private investment firm TE Asia Healthcare Partners and the Mother Teresa of Calcutta Medical Centre (MTCMC) in Pampanga have agreed to establish a Ps500 million (US$9.9 million) cancer treatment and management centre. The hospital is owned and operated by Silvermed Corporation.
Medical centre operator Primary Health Care has confirmed guidance for the year at the lower end of its guidance with expected net profits of A$92 million (US$73 million). It also flagged up a write down of A$575 million against its medical centres as the division has been underperforming.



Analysis

In what is starting to resemble a comedy of errors, Wenzhou Kangning Hospital, the largest private psychiatric specialty care service provider in China, is having to start work yet again for its A-share offering.
Singapore-based private equity firm Quadria Capital is expanding its holdings in the region with investments into Vietnam and Singapore from its third investment vehicle, Quadria Capital Fund. Financial details were not disclosed for either transaction.
Mental health is a growing issue for expats; workers and their employers, as well as those relocating independently, according to a recent research study by Aetna International. Expatriate mental health: breaking the silence and ending the stigma, calls for businesses and individuals to take more pre-emptive action to combat the problem, to ensure expats have the vital support they need when relocating or working away from their home country.
A new programme, launched by the Chinese Stroke Association (CSA) and the American Stroke Association (ASA) is aiming to improve the treatment for, and prevention of, cardiovascular and stroke events by helping hospitals and providers consistently adhere to the latest scientific treatment guidelines.
Brisbane-based Oventus has had a good week. First and foremost the sleep disorder device manufacturer has just completed the first tranche of capital raising. It has raised A$6.5 million (US$4.9 million) in a placement of shares at A$0.36 per share. A second tranche to raise A$0.5 million will follow subject to shareholder approval. Bell Potter is managing the deal.
A new report from QBE Insurance, Australia's largest global insurer, reveals that 22% of healthcare companies in Hong Kong have suffered from legal and regulatory compliance issues over the past 12 months. The Risks of Regret report looks at both current and future business challenges and opportunities, and how well-prepared companies are to deal with risks.
“The Asia-Pacific region presents lucrative opportunities for multinational pharmaceutical firms that treat diabetes,” says BMI Research in Singapore in a new report on healthcare in Asia. Fuelled by rapid urbanisation, nutrition transition and increasingly sedentary lifestyles, the epidemic has grown in parallel with the worldwide rise in obesity. Asia’s large population and rapid economic development have made it an epicentre of the epidemic, with India and China the key hotspots in the region, it explains.
Susann Roth, senior social development specialist, Asian Development Bank, explains why the ADB is committed to doubling health sector investments by 2020.


AON

HealthInvestor Asia Summit

Podcasts

Hedge Fund Focus

HealthInvestor Asia twitter feed
HIA Indices